Literature DB >> 29571940

Inhibiting core fucosylation attenuates glucose-induced peritoneal fibrosis in rats.

Longkai Li1, Nan Shen2, Nan Wang2, Weidong Wang2, Qingzhu Tang2, Xiangning Du2, Juan Jesus Carrero3, Keping Wang2, Yiyao Deng2, Zhitong Li4, Hongli Lin5, Taihua Wu6.   

Abstract

Ultrafiltration failure is a major complication of long-term peritoneal dialysis, resulting in dialysis failure. Peritoneal fibrosis induced by continuous exposure to high glucose dialysate is the major contributor of ultrafiltration failure, for which there is no effective treatment. Overactivation of several signaling pathways, including transforming growth factor-β1 (TGF-β1) and platelet-derived growth factor (PDGF) pathways, contribute to the development of peritoneal fibrosis. Therefore, simultaneously blocking multiple signaling pathways might be a potential novel method of treating peritoneal fibrosis. Previously, we showed that core fucosylation, an important posttranslational modification of the TGF-β1 receptors, can regulate the activation of TGF-β1 signaling in renal interstitial fibrosis. However, it remains unclear whether core fucosylation affects the progression of peritoneal fibrosis. Herein, we show that core fucosylation was enriched in the peritoneal membrane of rats accompanied by peritoneal fibrosis induced by a high glucose dialysate. Blocking core fucosylation dramatically attenuated peritoneal fibrosis in the rat model achieved by simultaneously inactivating the TGF-β1 and PDGF signaling pathways. Next the protective effects of blocking core fucosylation and imatinib (a selective PDGF receptor inhibitor) on peritoneal fibrosis were compared and found to exhibit a greater inhibitory effect over imatinib alone, suggesting that blocking activation of multiple signaling pathways may have superior inhibitory effects on the development of peritoneal fibrosis. Thus, core fucosylation is essential for the development of peritoneal fibrosis by regulating the activation of multiple signaling pathways. This may be a potential novel target for drug development to treat peritoneal fibrosis.
Copyright © 2018 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cell signaling; core fucosylation; fibrosis; peritoneal dialysis; peritoneal membrane; α-1,6 fucosyltransferase

Mesh:

Substances:

Year:  2018        PMID: 29571940     DOI: 10.1016/j.kint.2017.12.023

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  5 in total

1.  Spatial N-glycomics of the human aortic valve in development and pediatric endstage congenital aortic valve stenosis.

Authors:  Peggi M Angel; Richard R Drake; Yeonhee Park; Cassandra L Clift; Connor West; Savanna Berkhiser; Gary Hardiman; Anand S Mehta; David P Bichell; Yan Ru Su
Journal:  J Mol Cell Cardiol       Date:  2021-01-29       Impact factor: 5.000

2.  Blocking core fucosylation of epidermal growth factor (EGF) receptor prevents peritoneal fibrosis progression.

Authors:  Changqing Yu; Ning Yang; Weidong Wang; Xiangning Du; Qingzhu Tang; Hongli Lin; Longkai Li
Journal:  Ren Fail       Date:  2021-12       Impact factor: 2.606

3.  Positive association of serum FUT8 activity with renal tubulointerstitial injury in IgA nephropathy patients.

Authors:  Ning Yang; Long-Kai Li; Hui He; Xia-Nan Guo; Xue-Feng Yuan; Zhi-Tong Li; Wei-Dong Wang; Biao-Jie Qin; Xiang-Ning Du; Xu Zhang; Shu-Ni Chen; Hong-Li Lin
Journal:  Immun Inflamm Dis       Date:  2022-09

Review 4.  Mass spectrometry-based N-glycosylation analysis in kidney disease.

Authors:  Weifu Ren; Qi Bian; Yan Cai
Journal:  Front Mol Biosci       Date:  2022-08-17

5.  Angiotensin II type 2 receptor prevents extracellular matrix accumulation in human peritoneal mesothelial cell by ameliorating lipid disorder via LOX-1 suppression.

Authors:  Jing Liu; Bo Jin; Jian Lu; Yuan Feng; Nan Li; Cheng Wan; Qing-Yan Zhang; Chun-Ming Jiang
Journal:  Ren Fail       Date:  2022-12       Impact factor: 3.222

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.